David H. Persing, Executive VP, Chief Med/Tech Officer at CEPHEID (CPHD), sold 20,000 shares at $40.53 ($812K) on 2013-10-18, disclosed to the SEC on 2013-10-22.
Scheduled sale ($812k) by Executive VP, Chief Med/Tech Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $40.45 | 10,000 | $405K | 49.8% |
| 2 | $40.53 | 5,000 | $203K | 25.0% |
| 3 | $40.94 | 5,000 | $205K | 25.2% |
| Total | $40.59 avg | 20,000 | $812K | 100% |
| Filing → |
| CPHD | SELL | 2014-12-02 | $837K | — | Filing → |
| CPHD | SELL | 2014-12-01 | $4.1M | — | Filing → |
| CPHD | SELL | 2014-11-17 | $273K | — | Filing → |